Creative Medical Technology Holdings, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company specializing in regenerative medicine and immunotherapy. The company develops and commercializes cell-based therapies targeting unmet medical needs across immunology, endocrinology, urology, neurology, and orthopedics. Its product portfolio includes the AlloStem™ allogenic cell platform; ImmCelz™, an autologous immunotherapy platform leveraging secreted factors to enhance patient immune cells; iPSCelz™, a cellular reprogramming platform focused on induced pluripotent stem cells for various cell differentiation therapies; and rapid autologous therapy programs such as StemSpine®, OvaStem®, and CaverStem®. These platforms aim to address indications including chronic lower back pain, type 1 and type 2 diabetes, reproductive health, male and female sexual dysfunction, and orthopedic conditions. Headquartered in the United States and founded to pioneer innovative regenerative therapies, Creative Medical Technology Holdings operates globally with ongoing clinical trials and production capabilities, including cGMP clinical-grade cell manufacturing. Recent strategic advancements include securing FDA Fast Track designation for CELZ-201-DDT, an allogeneic cell therapy for degenerative disc disease, and obtaining World Health Organization approval for "olastrocel" as the International Nonproprietary Name (INN) for its lead allogeneic cell therapy CELZ-201. The company also announced significant mid-term follow-up data reporting substantial reduction in opioid use among chronic lower back pain patients treated with its StemSpine® procedure. Additionally, it achieved FDA clearance for expanded dosing in ongoing chronic back pain clinical trials and collaboration expansions with partners such as Greenstone Biosciences to advance the iPSCelz pipeline. Further recent milestones include receiving a notice of allowance for patents related to treatments of type 1 diabetes via immune modulation and for heart failure remodeling therapies with ImmCelz™. The company’s focus on efficient capital usage and strategic partnership development supports its clinical pipeline progression and broadening therapeutic scope. Creative Medical Technology Holdings is listed on NASDAQ under the ticker CELZ and continues to leverage proprietary regenerative platforms and extensive scientific expertise to advance a differentiated cell therapy franchise aimed at multi-billion-dollar therapeutic markets.
Creative Medical Technology Holdings Issues Mid-Year Update
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical Technology opens nationwide burn-pit data registry
Creative Medical Technology opens nationwide burn-pit data registry
Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
Bears are Losing Control Over Creative Medical Technology Holdings, Inc. (CELZ), Here's Why It's a 'Buy' Now
Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds
Creative Medical Technology Holdings Issues Letter to Shareholders
Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs
New Strong Sell Stocks for July 31st
Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells
Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling
Creative Medical Technology Holdings, Inc. (CELZ) Upgraded to Buy: What Does It Mean for the Stock?